Verrica Pharmaceuticals Inc. (VRCA) Stock Forecast
VRCA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.71 / 5 from 7 analysts
- Price target
- $13.83 average of analyst targets
- Upside to target
- +284.8% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-0.63
- 52-week range
- $3.28 – $9.10
VRCA analyst ratings
7 analystsNumber of analysts at each rating.
VRCA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
VRCA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.52 | −$0.57 | −$0.47 | $0.13 | −500.0% | 4 |
| Current fiscal year (2026) | −$1.97 | −$2.05 | −$1.84 | −$1.24 | −58.5% | 4 |
| Next fiscal year (2027) | −$1.48 | −$1.80 | −$1.12 | −$1.97 | +24.8% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
VRCA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $6.4M | $5.4M | $7.5M | −55.3% | 7 |
| Current fiscal year (2026) | $24.8M | $22.6M | $27.0M | −30.2% | 7 |
| Next fiscal year (2027) | $39.2M | $31.2M | $49.7M | +58.0% | 7 |
VRCA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
VRCA revenue: reported and forecast
VRCA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.43 | −$0.43 | −$0.52 | −$0.52 | −$0.52 | +21.9% | 0 up · 1 down |
| Current fiscal year (2026) | −$1.73 | −$1.73 | −$1.97 | −$1.97 | −$1.97 | +13.4% | 0 up · 1 down |
| Next fiscal year (2027) | −$1.24 | −$1.24 | −$1.48 | −$1.48 | −$1.48 | +18.8% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
VRCA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; VRCA beat in 9 of 12.
What analysts expect from VRCA
7 analysts cover Verrica Pharmaceuticals; their consensus rating is strong buy (4.71 on a 1–5 scale, where 5 is a strong buy). The average price target is $13.83, 284.8% above the latest close of $3.60. Analysts expect earnings of −$1.97 per share for 2026, −58.5% from a year earlier. For 2027 the average estimate is −$1.48 per share on revenue of $39.2 million. Verrica Pharmaceuticals beat the EPS estimate in 9 of the last 12 quarters.
Related: VRCA income statement, VRCA key metrics, VRCA chart. See the VRCA stock overview for the latest quote and news.
VRCA forecast FAQ
What is Verrica Pharmaceuticals's price target?
The average analyst price target for Verrica Pharmaceuticals is $13.83, 284.8% above the latest close of $3.60.
Is Verrica Pharmaceuticals a buy, hold or sell?
Of 7 analysts covering Verrica Pharmaceuticals, 6 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Verrica Pharmaceuticals's EPS forecast?
Analysts forecast −$1.97 per share for 2026 (range −$2.05 to −$1.84); for 2027 the estimate is −$1.48.
What is Verrica Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $24.8 million, growth of −30.2%; for 2027 it is $39.2 million.
When does Verrica Pharmaceuticals report earnings?
Verrica Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 13, 2026 after the market closes; the EPS estimate is $-0.63.
Does Verrica Pharmaceuticals usually beat earnings estimates?
Verrica Pharmaceuticals reported EPS at or above the analyst estimate in 9 of the last 12 quarters.